Sinovac Biotech (北京科兴生物制品有限公司) had the unhappy task of telling investors that revenue and profits declined in Q3. In the quarter, its flagship hepatitis A vaccine, Healive®, sold 28% fewer doses; AnFlu®, the flu vaccine, sold almost one-third fewer doses. As a result, Q3 revenues for the company were off by 19% at $10.8 million. Net income was more negatively affected: it was down 22%, plunging from $2.2 million last year to $740,000 in the most recent quarter. More details...

Stock Symbol: (AMEX: SVA)